Mon Dec 01 20:20:00 UTC 2025: Here’s a summary of the text and a rewritten news article:
Summary:
Eli Lilly has lowered the cash prices of single-dose vials of its weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect. This move follows similar price reductions by rival Novo Nordisk and comes after the Trump administration signed deals with both companies to improve access to GLP-1 drugs. The price reductions aim to address barriers to access created by Zepbound’s high list price and limited insurance coverage. The price of the starting dose has dropped from $349 to $299 per month. Lowering prices comes at the cost of lower revenues per medication, but demand is expected to remain high.
News Article:
Eli Lilly Cuts Zepbound Prices on LillyDirect Amid Competition, Accessibility Push
NEW YORK, NY – Eli Lilly announced Monday that it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug, Zepbound, through its direct-to-consumer platform, LillyDirect. The move aims to make the medication more accessible to patients paying out-of-pocket and follows similar discounts recently announced by competitor Novo Nordisk.
Starting immediately, patients with a valid prescription can purchase the starting dose of Zepbound for $299 per month, down from $349. Other doses are also discounted, with the 5mg dose available for $399 per month and all remaining doses priced at $449, previously $499. Zepbound’s list price is $1,086, but prices on LillyDirect will now offer much more accessible costs.
The price cut comes on the heels of President Donald Trump signing deals with Eli Lilly and Novo Nordisk to improve affordability and access to GLP-1 drugs. While the Trump administration agreements focused on multi-dose pens, Lilly’s reduction of single-dose vial prices offers immediate relief to patients who may not be able to afford the drug at its original list price due to limited insurance coverage for weight loss medications.
“We will keep working to provide more options — expanding choices for delivery devices and creating new pathways for access — so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement.
The news follows Novo Nordisk’s recent announcement of price reductions on its obesity drug Wegovy and diabetes treatment Ozempic for cash-paying patients. The companies are now battling it out to see who will win the weight loss medication crown.
Despite the lower prices, Eli Lilly is expected to see sales increase due to the surging demand for Zepbound and its diabetes injection Mounjaro. The company recently became the first healthcare company to achieve a $1 trillion market value, fueled by the success of these medications.
While Eli Lilly’s stock fell nearly 2% on Monday, analysts remain optimistic about the company’s long-term growth potential, particularly as it expands access to its key weight loss and diabetes treatments.
First Piper 